100683-08-7

Basic information

• Product Name: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID
• Synonyms: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID;Cyclopropanecarboxylic acid, 1-methoxy-
• CAS NO: 100683-08-7
• Molecular Formula: C₅H₈O₃
• Molecular Weight: 116.11522
• EINECS: -0
• Mol File: 100683-08-7.mol

Chemical Properties

• Boiling Point: 203.3±23.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• PKA: 3.67±0.20(Predicted)
• CAS DataBase Reference: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(100683-08-7)
• EPA Substance Registry System: 1-METHOXYCYCLOPROPANE-1-CARBOXYLIC ACID(100683-08-7)

Safety Data

• Hazardous Substances Data: 100683-08-7(Hazardous Substances Data)

Usage

Carboxylic acid derivative

A compound that has a carboxyl functional group (-COOH) attached to a hydrocarbon chain or ring.

Cyclopropane ring

A three-membered cyclic ring structure consisting of three carbon atoms with bond angles of 60 degrees, making it a strained and highly reactive ring system.

Methoxy group

An oxygen atom bonded to a methyl group (-OCH3), which is a functional group that can influence the reactivity and properties of the compound.

Precursor in synthesis

The compound serves as a starting material or building block in the synthesis of various pharmaceuticals and agrochemicals due to its unique structural features.

Potential role as a building block

1-Methoxycyclopropane-1-carboxylic acid has been studied for its possible use in the development of new organic materials and substances with specialized properties.

Biological activities and pharmacological effects

The compound has been investigated for its potential therapeutic effects in the treatment of certain medical conditions, although specific applications are not mentioned in the provided material.

Upstream product

• 2790-74-1 1-methoxycyclopropanecarboxylic acid methyl ester 
• 29526-97-4 1-methoxy-1-phenylcyclopropane 

Relevant articles and documents

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR

It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

STEROIDAL [3, 2-C] PYRAZOLE COMPOUNDS, WITH GLUCOCORTICOID ACTIVITY

The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

PYRROLOPYRIDINES AS KINASE INHIBITORS

Compounds of Formula (I) are useful for inhibition of CHKl and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

NOVEL FARNESYL PROTEIN TRANSFERASE INHIBITORS AS ANTITUMOR AGENTS

Disclosed are novel tricyclic compounds of the formula (I) and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.